Relationships between carbamazepine-diol, carbamazepine-epoxide, and carbamazepine total and free steady-state concentrations in epileptic patients: The influence of age, sex, and comedication

Therapeutic Drug Monitoring

Volumn 18, Issue 6, 1996, Pages 660-665

  Svinarov, D A ^a   Pippenger, C E ^b  

^a MEDICAL UNIVERSITY OF SOFIA   (Bulgaria)

^b FRESA BioMedical Laboratories   (United States)

Author keywords

Age influence; Carbamazepine; Dose ratio; Drug interaction; Metabolite

Indexed keywords

10,11 DIHYDRO 10,11 DIHYDROXYCARBAMAZEPINE; ANTICONVULSIVE AGENT; CARBAMAZEPINE; CARBAMAZEPINE 10,11 OXIDE; CLONAZEPAM; DRUG METABOLITE; ETHOSUXIMIDE; MEPHENYTOIN; PHENOBARBITAL; PHENYTOIN; VALPROIC ACID;

ADOLESCENT; ADULT; AGE; AGED; ANTICONVULSANT THERAPY; ARTICLE; CHILD; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG MONITORING; DRUG PROTEIN BINDING; EPILEPSY; FEMALE; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; NEWBORN; PRIORITY JOURNAL; SEX;

ADOLESCENT; ADULT; AGE FACTORS; AGED; ANTICONVULSANTS; CARBAMAZEPINE; CHILD; CHILD, PRESCHOOL; DRUG INTERACTIONS; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; FEMALE; HUMANS; INFANT; MALE; MIDDLE AGED; PHENOBARBITAL; PROTEIN BINDING; SEX FACTORS;

EID: 0029830503     PISSN: 01634356     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007691-199612000-00006     Document Type: Article

References (32)

1. Rapeport WG. Factors influencing the relationship between carbamazepine plasma concentration and its clinical effects in patients with epilepsy. Clin Neuropharmacol 1985;8:141-9.
2. MacKichan JJ. Carbamazepine. In: Taylor WJ, Caviness MHD, eds. A textbook for the clinical application of therapeutic drug monitoring. Irving: Abbott Laboratories, 1986:211-24.
3. Bertilsson L, Tomson T. Clinical pharmacokinetics and pharmacological effects of carbamazepine and carbamazepine-10,11-epoxide. Clin Pharmacokinet 1986;11:177-98.
4. Gonzales ACA, Sanchez MJG, Hurle AD-G. Intra- and interindividual relationship between serum levels and dose in epileptic patients treated with carbamazepine monotherapy. Ther Drug Monit 1988;10:501-3.
5. Liu H, Delgado M. Improved therapeutic monitoring of drug interactions in epileptic children using carbamazepine polytherapy. Ther Drug Monit 1994;16:132-8.
6. McKauge L, Tyrer JH, Eadie MJ. Factors influencing simultaneous concentrations of carbamazepine and its epoxide in plasma. Ther Drug Monit 1981;3:63-70.
7. Lindhout D, Hoppener RJEA, Meinardi H. Teratogenicity of antiepileptic drug combinations with special emphasis on epoxidation (of carbamazepine). Epilepsia 1984;25:77-83.
8. Schoeman JF, Elyas AA, Brett EM, Lascelles PT. Altered ratio of carbamazepine-10,11-epoxide/carbamazepine in plasma of children: evidence of anticonvulsant drug interaction. Dev Med Child Neurol 1984;26:749-55.
9. Furlanut M, Montanari G, Bonin P, Casara GL. Carbamazepine and carbamazepine-10,11-epoxide in epileptic children. J Pediatr 1985;26:491-5.
10. Riva R, Contin M, Albani F, Perucca E, Lamontanara G, Baruzzi A. Free and total serum concentrations of carbamazepine and carbamazepine-10,11-epoxide in infancy and childhood. Epilepsia 1985;26:320-2.
11. Riva R, Contin M, Albani F, Perucca E, Procaccianti G, Baruzzi A. Free concentration of carbamazepine and carbamazepine-10,11-epoxide in children and adults. Influence of age and phenobarbitone comedication. Clin Pharmacokinet 1985;10:524-31.
12. Elyas AA, Patsalos PN, Agbato OA, Brett EM, Lascelles PT. Factors influencing simultaneous concentrations of total and free carbamazepine and carbamazepine-10,11-epoxide in serum of children with epilepsy. Ther Drug Monit 1986;8:288-92.
13. Pisani F, Fazio A, Oteri G, et al. Sodium valproate and valpromide: differential interactions with carbamazepine in epileptic patients. Epilepsia 1986;27:548-52.
14. Altafullah I, Talwar D, Loewenson R, Olson K, Lockman LA. Factors influencing serum levels of carbamazepine and carbamazepine-10,11-epoxide in children. Epilepsy Res 1989;4:72-80.
15. Ramsay RE, McManus DQ, Guterman A, et al. Carbamazepine metabolism in humans: effect of concurrent anticonvulsant therapy. Ther Drug Monit 1990;12:235-41.
16. Spina E, Martines C, Fazio A, Pisani F, Tomson T. Effect of phenobarbital on the pharmacokinetics of carbamazepine-10,11-epoxide, an active metabolite of carbamazepine. Ther Drug Monit 1990;13:109-12.
17. Wang R-B, Liu L, Yiu C. Carbamazepine drug interactions: the influence of concurrent drug therapy on serum concentrations of carbamazepine and its epoxide metabolite [Abstract]. Quim Clin 1990;4:363.
18. Bourgeois BFD, Wad N. Carbamazepine-10,11-diol steady state serum levels and renal excretion during carbamazepine therapy in adults and children. Ther Drug Monit 1984;6:259-65.
19. Rambeck B, May T, Juergens U. Serum concentration of carbamazepine and its epoxide and diol metabolites in epileptic patients: the influence of dose and comedication. Ther Drug Monit 1987; 9:298-303.
20. Tomson T, Svensson JO, Hilton-Brown P. Relationship of dose to plasma concentration of carbamazepine: indication of dose-dependent induction of metabolism. Ther Drug Monit 1989;11: 533-9.
21. Grosman M, Grosman M, Rubio MC, Alvarez F. Effect of anticonvulsant drugs on carbamazepine metabolism, measure trough the monitoring of its metabolites [Abstract]. Clin Chem 1990;36: 1036.
22. Hatrley R, Lucock MD, Ng PC, Forythe WI, Bowmer CJ. Factors influencing plasma level/dose ratios of carbamazepine and its major metabolites in epileptic children. Ther Drug Monit 1990;12: 438-44.
23. Liu H, Delgado M, Iannaccone ST, Forman LJ, Eggers CM. Determination of total and free carbamazepine and the principal metabolites in serum by high-performance liquid chromatography with photodiode-array detection. Ther Drug Monit 1993;15:317-27.
24. Svinarov D, Dotchev D. Simultaneous liquid chromatographic determination of some bronchodilators, anticonvulsants, chloramphenicol and hypnotic agents with Chromosorb P columns used for sample preparation. Clin Chem 1989;35:1615-8.
25. Suzuki Y, Cox S, Hayes J, Walson PD. Carbamazepine age-dose ratio relationship in children. Ther Drug Monit 1991;13:201-8.
26. Agbato OA, Elyas AA, Patsalos PN, Brett EM, Lascelles PT. Total and free serum concentrations of carbamazepine and carbamazepine-10,11-epoxide in children with epilepsy. Arch Neurol 1986; 33:1111-6.
27. MacKichan JJ, Dufner PK, Cohen ME. Salivary concentrations and plasma protein binding of carbamazepine and carbamazepine-10,11-epoxide in epileptic patients. Br J Clin Pharmacol 1981;12: 31-7.
28. Vree TB, Janssen TJ, Hekster YA, Termond EFS, van de Dries ACP, Wijnands WJA. Clinical pharmacokinetics of carbamazepine and its epoxy and hydroxy metabolites in humans after an over-dose. Ther Drug Monit 1986;8:297-304.
29. Albani F, Riva R, Contin M, Baruzzi A. A within-subject analysis of carbamazepine disposition related to development in children with epilepsy. Ther Drug Monit 1992;14:457-60.
30. Tomson TE, Spina E, Wedlund JE. Minor additive inducing effects of phenobarbital on carbamazepine clearance in patients on combined carbamazepine-phenytoin therapy. Ther Drug Monit 1987; 9:117-9.
31. Zielinski JJ, Haidukewych D. Dual effects of carbamazepine-phenytoin interaction. Ther Drug Monit 1987;9:21-3.
32. Svinarov DA, Pippenger CE. Valproic acid-carbamazepine interaction: is valproic acid a selective inhibitor of epoxide hydrolase? Ther Drug Monit 1995;17:217-20.